株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バンコマイシン耐性腸球菌感染症:パイプライン製品の分析

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 264091
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
バンコマイシン耐性腸球菌感染症:パイプライン製品の分析 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2017
出版日: 2017年05月23日 ページ情報: 英文 79 Pages
概要

バンコマイシン耐性腸球菌の病原性株は、VREと呼ばれ、院内感染の原因となっています。症状は、感染部位によって異なります。細菌は通常、腸・創傷・尿路で感染します。創傷感染の場合は、感染部位は赤く、圧痛があり、腫れます。尿路感染の場合は、背中の痛み、排尿時の灼熱感が生じます。他には、悪心、発熱、悪寒、激しい頭痛、下痢などの症状が見られます。予防には、効果的な衛生の実行が不可欠です。

当レポートでは、バンコマイシン耐性腸球菌感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

バンコマイシン耐性腸球菌感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Alchemia Ltd
  • Aphios Corp
  • C3J Therapeutics Inc
  • Helix BioMedix Inc
  • Hsiri Therapeutics LLC
  • LegoChem Biosciences Inc
  • Lytix Biopharma AS
  • MGB Biopharma Ltd
  • MicuRx Pharmaceuticals Inc
  • Nanotherapeutics Inc
  • NovoBiotic Pharmaceuticals LLC
  • Oragenics Inc
  • Ovensa Inc
  • Sealife PHARMA GMBH
  • Wockhardt Ltd

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9336IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2017, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 17 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vancomycin-Resistant Enterococcus faecium Infections - Overview
    • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
    • Alchemia Ltd
    • Aphios Corp
    • C3J Therapeutics Inc
    • Helix BioMedix Inc
    • Hsiri Therapeutics LLC
    • LegoChem Biosciences Inc
    • Lytix Biopharma AS
    • MGB Biopharma Ltd
    • MicuRx Pharmaceuticals Inc
    • Nanotherapeutics Inc
    • NovoBiotic Pharmaceuticals LLC
    • Oragenics Inc
    • Ovensa Inc
    • Sealife PHARMA GMBH
    • Wockhardt Ltd
  • Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles
    • AM-218 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chrysophaentin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • closthioamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-1345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HT-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-010371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LTX-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Marinus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRX-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRX-IV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAI-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAI-108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAI-603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OG-253 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ramoplanin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0904 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0905 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Bacterial Cell Wall for Vancomycin-Resistant Enterococcus faecium and Staphylococcus aureus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Teixobactin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WCK-4086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
  • Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
    • Featured News & Press Releases
      • Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4
      • Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
      • Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
      • Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
      • May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
      • Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Ltd, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by C3J Therapeutics Inc, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix Inc, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences Inc, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Nanotherapeutics Inc, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Ovensa Inc, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2017
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top